Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6838758 | 0.99 | ADORA3 (0.45) | ADORA3TLR7USP2POLBNPY1R | |
| SCHEMBL6833984 | 0.88 | ADORA3 (0.37) | ADORA3TLR7NPY1RRXRARXRB | |
| SCHEMBL6837685 | 0.87 | ADORA3 (0.40) | ADORA3NPY1RTP53MAPT | |
| SCHEMBL6833816 | 0.87 | ADORA3 (0.37) | ADORA3TLR7POLBRXRARXRB | |
| SCHEMBL6838083 | 0.87 | ADORA3 (0.36) | ADORA3NPY1RCHRM1HRH1 | |
| SCHEMBL7488417 | 0.86 | NPY1R (0.36) | ADORA3TLR7NPY1RRXRARXRB | |
| SCHEMBL6838584 | 0.86 | ADORA3 (0.39) | ADORA3NPY1R | |
| SCHEMBL6840005 | 0.86 | ADORA3 (0.35) | ADORA3TLR7NPY1RRXRARXRB | |
| SCHEMBL6840151 | 0.85 | HTR4 (0.41) | TLR7NPY1RHTR4 | |
| SCHEMBL6838070 | 0.85 | NPY1R (0.37) | ADORA3TLR7NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1256582-A1 | 1H-IMIDAZOPYRIDINE DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | IL2, IL1A, IL4 | ADORA3 3201/4885TLR7 964/4885USP2 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.